Novel signalling cascade for cardiac hypertrophy activation by uncoupling and internalization of β1-adrenoceptors

Cardiovascular Research

Volumn 78, Issue 1, 2008, Pages 5-7

  Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA 1 ADRENERGIC RECEPTOR; CATECHOLAMINE; CYTOKINE; DIACYLGLYCEROL; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE RECEPTOR; PHENYLEPHRINE; PROTEIN KINASE C;

ANIMAL CELL; CONTROLLED STUDY; DISEASE PREDISPOSITION; EDITORIAL; ENDOCYTOSIS; GENE OVEREXPRESSION; HEART ASSIST DEVICE; HEART FAILURE; HEART HYPERTROPHY; HEART RATE; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-AGONISTS; ANIMALS; CARDIOMEGALY; CELL SIZE; ENDOCYTOSIS; HUMANS; MYOCYTES, CARDIAC; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 41149153308     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn042     Document Type: Editorial

References (24)

1. Vatner SF, Vatner DE, Homcy CJ. β-Adrenergic receptor signalling: an acute compensatory adjustment - inappropriate for the chronic stress of heart failure? Insights from Gsα overexpression and other genetically engineered animal models. Circ Res 2000;86:502-506.
2. Liao R, Force T. Not all hypertrophy is created equal. Circ Res 2007;101:1069-1072.
3. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
4. Takahashi H, Takeishi Y, Seidler T, Arimoto T, Akiyama H, Koyama Y et al. Adenovirus-mediated overexpression of diacylglycerol kinase ζ inhibits endothelin-1-induced cardiomyocyte hypertrophy. Circulation 2005;111:1510-1516.
5. Arimoto T, Takeishi Y, Takahashi H, Shishido T, Niizeki T, Koyama Y et al. Cardiac-specific overexpression of diacylglycerol kinase ζ prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice. Circulation 2006;113:60-66.
6. Dorn GW II. Adrenergic pathways and left ventricular remodeling. J Card Fail 2002;8 (Suppl. 6):S370-S373.
7. 1B-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 2003;111:1783-1791.
8. 1-Adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 2006;116: 1005-1015.
9. 1b- adrenergic receptor-induced cardiac hypertrophy by oligonucleotide arrays. Cardiovasc Res 2003;57:443-455.
10. Zhai P, Yamamoto M, Galeotti J, Liu J, Masurekar M, Thaisz J et al. Cardiac specific overexpression of AT1 receptor mutant lacking Gαq/Gαi coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest 2005;115:3045-3056.
11. 1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes. Cardiovasc Res 2008;78:36-44.
12. 1-subtype in the rat heart. J Mol Cell Cardiol 2001;33:561-573.
13. Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ et al. Alterations in cardiac adrenergic signalling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest 2002;107:967-974.
14. Tachibana H, Naga Prasad SV, Lefkowitz RJ, Koch WJ, Rockman HA. Level of β-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure. Circulation 2005;111:591-597.
15. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E. G-protein-coupled receptor internalization signalling is required for cardioprotection in ischemic preconditioning. Circ Res 2004;94:1133-1141.
16. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Schneider W, Loser P et al. Requirement of nuclear factor-κ B in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 2005;111:2319-2325.
17. Kawauchi-Manabe H, Ieda M, Kimura K, Manabe T, Miyatake S, Kanazawa H et al. A novel cardiac hypertrophic factor, neurotrophin-3, is paradoxically downregulated in cardiac hypertrophy. Life Sci 2007;81:385-392.
18. Flaherty MP, Brown M, Grupp IL, Schultz JE, Murphree SS, Jones WK. eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression. Cardiovasc Toxicol 2007;7:165-177.
19. Laskowski A, Woodman OL, Cao AH, Drummond GR, Marshall T, Kaye DM et al. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 2006;72:112-123.
20. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 2003;93:69-76.
21. -/- mice in response to chronic pressure overload. Cardiovasc Res 2008;78:79-89.
22. Dorn GW II, Tepe NM, Wu G, Yatani A, Liggett SB. Mechanisms of impaired β-adrenergic signalling in Gαq-mediated cardiac hypertrophy and ventricular dysfunction. Mol Pharmacol 2000;57:278-287.
23. Schotten U, Filzmaier K, Borghardt B, Kulka S, Schoendube F, Schumacher C et al. Changes of β-adrenergic signalling in compensated human cardiac hypertrophy depend on the underlying disease. Am J Physiol Heart Circ Physiol 2000;278:H2076-H2083.
24. Katz AM. Heart Failure: Pathophysiology, Molecular Biology, and Clinical Management. Lippincott Williams & Wilkins, A Wolters Kluwer Co, Philadelphia; 2000.